Springer Nature
Browse

sorry, we can't preview this file

12885_2019_5704_MOESM5_ESM.tif (1.18 MB)

Additional file 5: of Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Download (1.18 MB)
figure
posted on 2019-05-23, 05:00 authored by Huan Deng, Yu Huang, Zhengdong Hong, Xuhui Yuan, Zhi Cao, Yiping Wei, Wenxiong Zhang
Figure S4. Begg’s and Egger’s tests for comparisons of ORR (A) and DCR (B) associated with pazopanib versus sunitinib. (TIF 1210 kb)

Funding

National Natural Science Foundation of China

History

Usage metrics

    BMC Cancer

    Categories

    Keywords

    Meta-analysisPazopanibSunitinibTargeted therapyRenal cell carcinoma

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC